Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novozymes A/S    NZYM B   DK0060336014


Real-time Estimate Quote. Real-time Estimate Cboe Europe - 03/30 11:29:06 am
308.1 DKK   +1.15%
07:06aNOVOZYMES A/S : Transactions under Novozymes' stock buyback program
03/27NOVOZYMES A/S : Reduction of share capital
03/16NOVOZYMES A/S : Transactions under Novozymes' stock buyback program
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Novozymes A/S : acquires Organobalance GmbH to strengthen position in microbial solutions

share with twitter share with LinkedIn share with facebook
share via e-mail
09/15/2016 | 03:13am EDT

Novozymes today announces the acquisition of microbial research company Organobalance GmbH for an undisclosed amount. Germany-based Organobalance owns a large collection of microbial strains, some of which date back to the 1920s, and has strong capabilities in microbial screening and assay technology. It specializes in developing natural microbial solutions for customers and partners across a number of industries including food, feed, and animal health.

'The experience of Organobalance's founding scientists, and the company's know-how, immediately strengthen Novozymes' existing capabilities within microbial technologies,' says Sebastian Søderberg, Vice President for New Business Development, Incubation & Acquisitions at Novozymes. 'Organobalance will advance our understanding to develop new, sustainable solutions across industries, and provide us with additional commercial opportunities.'

'Organobalance, our employees and customers will benefit greatly from this move,' says Prof. Dr Christine Lang who co-founded Organobalance and will continue as General Manager. 'By becoming part of Novozymes, we will have access to a global R&D network and an extensive infrastructure to bring products to market - a clear advantage for us and our customers. When two well-established companies such as Novozymes and Organobalance team up in biological research to confront challenges in technology and society, it benefits people and the wider bioeconomy of Germany.'

Similar ambitions and company cultures

Based in Berlin and Flensburg, in Germany, Organobalance has 29 employees and was co-founded in 2001 by Prof. Dr Lang. Following the acquisition, Organobalance will be integrated into Novozymes' global organization but will continue to be based in Germany so as to benefit from the established biotechnology capabilities of the country's capital region and the company's strong ties to German academia, innovation environments, and markets.

'Organobalance and Novozymes possess similar ambitions and company cultures,' says Sebastian Søderberg. 'Both companies strongly believe that innovative biological solutions can make a real, positive difference in the world and help tackle many of modern society's biggest challenges. Together, our solutions fundamentally allow customers to produce more from less, reduce environmental impact, improve health and replace chemicals.'

The acquisition will not impact Novozymes' financial outlook for 2016.

What are microbes?

Microbials or microbes are microorganisms. These are microscopic living organisms, existing either as one cell or with multiple cells. They are classified into various groups, including fungi (yeasts and molds) and bacteria. Microbials can produce beneficial compounds such as enzymes or biochemicals, which can be obtained through industrial fermentation, a process by which microbials grow and are able to turn simple inputs such as sugar into more complex molecules. Sometimes, microbials can be the end product, as is the case within the area of biological agriculture.

Media contact: Frederik Bjørndal

Novozymes A/S published this content on 15 September 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 15 September 2016 07:13:06 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVOZYMES A/S
07:06aNOVOZYMES A/S : Transactions under Novozymes' stock buyback program
03/27NOVOZYMES A/S : Reduction of share capital
03/16NOVOZYMES A/S : Transactions under Novozymes' stock buyback program
03/09NOVOZYMES : Transactions under Novozymes' stock buyback program
03/02NOVOZYMES : Transactions under Novozymes' stock buyback program
02/27NOVOZYMES AS : Ex-dividend day for final dividend
02/26NOVOZYMES : New incentive programs for the Executive Leadership Team, the Senior..
02/26NOVOZYMES A/S : ' annual shareholders' meeting 2020
02/24NOVOZYMES : Transactions under Novozymes' stock buyback program
02/17NOVOZYMES : Transactions under Novozymes' stock buyback program
More news
Financials (DKK)
Sales 2020 14 885 M
EBIT 2020 4 031 M
Net income 2020 3 091 M
Debt 2020 3 963 M
Yield 2020 1,79%
P/E ratio 2020 27,8x
P/E ratio 2021 25,8x
EV / Sales2020 6,06x
EV / Sales2021 5,84x
Capitalization 86 210 M
Duration : Period :
Novozymes A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOZYMES A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 18
Average target price 328,88  DKK
Last Close Price 306,00  DKK
Spread / Highest target 37,9%
Spread / Average Target 7,48%
Spread / Lowest Target -10,1%
EPS Revisions
Ester Baiget President & Chief Executive Officer
Jørgen Buhl Rasmussen Chairman
Thomas Videbaek COO, Executive VP-Research, Innovation & Supply
Lars Green Chief Financial Officer & Executive Vice President
Claus Crone Fuglsang VP-Franklinton Biofuel, Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
NOVOZYMES A/S-6.56%12 736
ECOLAB INC.-16.37%45 538
HENKEL AG & CO. KGAA-22.69%32 482
GIVAUDAN-5.48%27 617
SIKA AG-13.75%23 248